185 related articles for article (PubMed ID: 25671235)
21. Treatment landscape of metastatic prostate cancer: the role of radium-223.
Dermine A; Machiels JP
Acta Clin Belg; 2017 Feb; 72(1):19-23. PubMed ID: 27377415
[TBL] [Abstract][Full Text] [Related]
22. Radium-223 in metastatic castration resistant prostate cancer.
Vuong W; Sartor O; Pal SK
Asian J Androl; 2014; 16(3):348-53. PubMed ID: 24713838
[TBL] [Abstract][Full Text] [Related]
23. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
[TBL] [Abstract][Full Text] [Related]
24. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558
[TBL] [Abstract][Full Text] [Related]
25. Updates on radium-223 for castration-resistant prostate cancer presented at the Genitourinary Cancers Symposium, January 7-9, 2016, San Francisco, California.
Barkin J
Can J Urol; 2016 Jun; 23(3):8306-7. PubMed ID: 27347626
[No Abstract] [Full Text] [Related]
26. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
Poeppel TD; Handkiewicz-Junak D; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Sonnenschein W; Bodei L; Delgado-Bolton RC; Gabriel M
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):824-845. PubMed ID: 29234845
[TBL] [Abstract][Full Text] [Related]
27. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.
Nilsson S; Strang P; Aksnes AK; Franzèn L; Olivier P; Pecking A; Staffurth J; Vasanthan S; Andersson C; Bruland ØS
Eur J Cancer; 2012 Mar; 48(5):678-86. PubMed ID: 22341993
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer bone metastases: not so systemic after all.
Logothetis CJ
Lancet Oncol; 2014 Jun; 15(7):675-6. PubMed ID: 24836275
[No Abstract] [Full Text] [Related]
29. Radium-223 dichloride in clinical practice: a review.
Florimonte L; Dellavedova L; Maffioli LS
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
[TBL] [Abstract][Full Text] [Related]
30. Targeted α Therapies for the Treatment of Bone Metastases.
Zustovich F; Barsanti R
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29283383
[TBL] [Abstract][Full Text] [Related]
31. Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer.
Buroni FE; Persico MG; Pasi F; Lodola L; Nano R; Aprile C
Anticancer Res; 2016 Nov; 36(11):5719-5730. PubMed ID: 27793893
[No Abstract] [Full Text] [Related]
32. Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
Wale DJ; Viglianti BL; Gross MD; Ferretti A; Rubello D; Wong KK
Am J Clin Oncol; 2019 Jan; 42(1):99-106. PubMed ID: 30204613
[TBL] [Abstract][Full Text] [Related]
33. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
[TBL] [Abstract][Full Text] [Related]
34. [Radium-223 for the treatment of bone metastasis of prostate cancer].
Xu XF; Wei ZF; Zhang ZY
Zhonghua Nan Ke Xue; 2017 Jan; 23(1):78-81. PubMed ID: 29658243
[TBL] [Abstract][Full Text] [Related]
35. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
37. Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation.
Hosono M; Ikebuchi H; Nakamura Y; Yanagida S; Kinuya S
Ann Nucl Med; 2019 Mar; 33(3):211-221. PubMed ID: 30484260
[TBL] [Abstract][Full Text] [Related]
38. Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.
Iizuka J
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():16-23. PubMed ID: 30489033
[TBL] [Abstract][Full Text] [Related]
39. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
Jong JM; Oprea-Lager DE; Hooft L; de Klerk JM; Bloemendal HJ; Verheul HM; Hoekstra OS; van den Eertwegh AJ
Eur Urol; 2016 Sep; 70(3):416-26. PubMed ID: 26391636
[TBL] [Abstract][Full Text] [Related]
40. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
Jadvar H; Challa S; Quinn DI; Conti PS
Cancer Biother Radiopharm; 2015 Jun; 30(5):195-9. PubMed ID: 25746633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
